Study guide
11.1 Monitoring Preparation and Visit Types
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
11.1 Monitoring Preparation and Visit Types
Key Takeaways Explain This Topic AI
Monitoring ensures the rights, safety, and well-being of trial subjects are protected.
Preparation involves updating the Investigator Site File (ISF), resolving queries, and ensuring staff availability.
Risk-based monitoring (RBM) focuses on critical data and processes, often utilizing centralized monitoring.
Last updated: October 2026
11.1 Monitoring Preparation and Visit Types
Monitoring is a fundamental component of clinical research, mandated by ICH GCP guidelines to ensure that human subject rights are protected, reported trial data are accurate, complete, and verifiable, and the trial is conducted in compliance with the approved protocol. For the Clinical Research Coordinator (CRC), facilitating monitoring visits is a core responsibility that requires meticulous organization and proactive communication.
The Purpose of Monitoring
Under ICH E6(R3), monitoring is one of the sponsor's principal quality control activities, aimed at protecting participants and the reliability of trial results (section 3.11.4). The Clinical Research Associate (CRA), acting on behalf of the sponsor or Contract Research Organization (CRO), serves as the primary liaison between the sponsor and the research site. Their objective is not merely to find errors but to ensure patient safety and data integrity through proactive oversight. The CRA evaluates whether the site has adequate resources, follows the approved protocol, properly dispenses and accounts for the Investigational Product (IP), and accurately reports adverse events.
Types of Monitoring Strategies
The traditional model of 100% on-site Source Data Verification (SDV) has evolved significantly. Regulatory agencies like the FDA and EMA now encourage more targeted, efficient approaches that prioritize critical data and processes.
1. On-Site Monitoring
The CRA physically visits the research site. This allows for a direct review of physical facilities (e.g., pharmacy, laboratories), face-to-face interaction with site staff, and manual review of the Investigator Site File (ISF) and paper source documents. On-site monitoring remains crucial for building the sponsor-site relationship and verifying elements that cannot be assessed remotely.
2. Centralized Monitoring
Data is evaluated remotely and continuously at the sponsor/CRO level by data managers and statisticians. By analyzing trends across the entire trial, centralized monitoring can identify anomalous data, missing data, or protocol deviations across sites or within a specific site. For example, if a site consistently reports zero adverse events while all other sites report an average of three per subject, centralized monitoring will flag this as a potential issue. Centralized monitoring complements on-site visits and can trigger a targeted "for-cause" on-site visit if concerning trends are identified.
3. Risk-Based Monitoring (RBM) and RBQM
Risk-Based Quality Management (RBQM) and Risk-Based Monitoring (RBM) are strategic approaches that direct monitoring resources to the areas of greatest risk. Instead of verifying every single data point for every subject, RBM focuses on critical data variables (e.g., primary efficacy endpoints, serious adverse events, informed consent documentation). RBM utilizes predefined Key Risk Indicators (KRIs).
- Common Key Risk Indicators (KRIs) Potential Concern Indicated
- High rate of protocol deviations Misunderstanding of protocol, inadequate training
- High screen failure rate Unrealistic inclusion/exclusion criteria, poor pre-screening
- Delayed EDC data entry Resource constraints at the site, increased risk of data loss
- Excessive query rates CRC errors, complex eCRF design, lack of source data
- 4. Remote Monitoring
Remote monitoring involves the CRA reviewing site documentation and data without traveling to the site. This became particularly prominent during the COVID-19 pandemic and has remained a staple. Sites may grant CRAs limited, secure "read-only" access to Electronic Medical Records (EMRs) or upload redacted source documents to a secure, 21 CFR Part 11 compliant portal for review.
Source Data Verification (SDV) vs. Source Data Review (SDR)
When preparing for monitoring, CRCs must understand the difference between SDV and SDR, as CRAs will perform both:
Source Data Verification (SDV): The process of matching the data entered into the Electronic Data Capture (EDC) system with the original source document to ensure accuracy. For example, checking that the blood pressure entered in the EDC matches the clinic note.
Source Data Review (SDR): A qualitative review of the source documentation to ensure compliance with the protocol, GCP, and site Standard Operating Procedures (SOPs). For example, reviewing a clinic note to ensure the physician documented the clinical significance of an out-of-range lab value, even if that specific note isn't transcribed into the EDC.
Preparing for a Monitoring Visit
Thorough preparation by the CRC is critical for a successful monitoring visit. Unprepared sites can lead to prolonged visits, negative monitoring reports, and compromised data integrity.
Scheduling and Logistics
Confirm Availability : Ensure the Principal Investigator (PI), sub-investigators, and CRC are available. The PI typically needs a 15-30 minute wrap-up meeting with the CRA to discuss findings and sign off on major issues.
Reserve Space : Secure a quiet, private location for the CRA to work, ensuring access to necessary equipment (Wi-Fi, power, secure EMR access).
Notify Departments : Inform the investigational pharmacy, laboratory, or other relevant departments that the CRA will be arriving, especially if a facility tour or IP accountability check is required.
Updating the Investigator Site File (ISF)
The ISF (or regulatory binder) must be current and inspection-ready at all times. Prior to the visit, the CRC should:
File all recent IRB approvals, continuing reviews, and safety reports (e.g., SUSARs, IND safety reports).
Ensure the Delegation of Authority (DOA) log accurately reflects current staff and tasks, and is signed by the PI.
Verify that all staff training logs and CVs/licenses are up-to-date.
Ensure the site visit log is printed and ready for the CRA to sign immediately upon arrival.
Electronic Case Report Form (eCRF) and Data Management
Enter all outstanding data into the EDC system prior to the visit, adhering to the sponsor's data entry timelines.
Resolve any open queries generated by the data management team or previous monitoring visits.
Ensure source documents are organized, signed and dated by the PI where necessary (e.g., laboratory reports, ECGs), and match the data entered into the EDC.
Investigational Product (IP) Accountability
Ensure IP logs (receipt, dispensing, return, and destruction) are completely up-to-date.
Check temperature logs to confirm there were no unreported excursions. If an excursion occurred, ensure it was reported to the sponsor and IP was quarantined until approved for use.
Ensure used and unused IP are appropriately stored, segregated, and ready for CRA review.
The CRA-CRC Relationship
The dynamic between the CRA and CRC is vital to the success of the trial at the site level. While the CRA's role includes identifying discrepancies and enforcing compliance, a collaborative, professional approach yields the best results. The CRC should view the CRA as a resource to help clarify protocol ambiguities, facilitate sponsor communication, and ensure the site remains compliant. Transparency is key; if a CRC discovers a protocol deviation or an error, it is always better to self-report and document it rather than waiting for the CRA to find it during a visit.